First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. 4A10 is a targeted therapy designed to recognize and attach to a specific protein (CD127) found on leukemia cells. Once it binds, it works in two ways: it blocks growth signals that help cancer cells survive, and it helps the immune system find and destroy those cancer cells. In this study, patients receive 4A10 through an intravenous (IV) infusion once a week. The main goal of the trial is to find out if the drug is safe, what dose can be given, and how the body processes it. Researchers will also look for early signs that the treatment may be working. The study starts with small groups of patients receiving increasing doses to carefully monitor safety. Each patient is closely observed during the first treatment cycle (about 4-6 weeks) to watch for side effects. If the treatment is helping and is well tolerated, patients may continue treatment for up to six cycles. Overall, this study is an early step in testing a new, targeted immune-based therapy for difficult-to-treat blood cancers.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza białaczki limfoblastycznej (ALL) lub chłoniaka limfoblastycznego
- •Choroba nawrotowa lub oporna na leczenie, bez dostępnych opcji kuracyjnych
- •Wystarczająco dobrze funkcjonujące narządy wewnętrzne
✗ Disqualifies
- •Zaawansowana choroba z przerzutami do ośrodkowego układu nerwowego
- •Zaburzenia genetyczne wpływające na stabilność DNA (zespół Fanconi, zespół Blooma) lub trisomia 21 (zespół Downa)
- •Wcześniejsze leczenie lekami nakierowanymi na białko CD127
- •Niekontrolowane infekcje
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Children's Hospital Colorado
Aurora, United States
Children's Hospital of Philadelphia
Philadelphia, United States
Cook Children's Medical Center
Fort Worth, United States
Texas Children's Hospital
Houston, United States
Trial contact
Shibani M Kudchadkar, MD
Yan Moore, MD, MBA
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.